Search | Clinical Trials Finder

Conditions: Peripheral Artery Disease
Interventions: PRT-201; Drug
Lead sponsor: Proteon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Atherosclerosis, Lower Extremity Ischemia, Claudication, Rest Pain
Interventions: Femoral-popliteal Bypass, Angioplasty and stent placement with Viabahn covered stent-graft(W.L. Gore & Associates, Flagstff, Arizona) of superficial femoral artery; Procedure · Device
Lead sponsor: Texas Vascular Associates; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Leukodystrophy, White Matter Disease, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts 1, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication &#X7C; Blood or Tissue &#X7C; Mutations, Pelizaeus-Merzbacher-Like Disease, 1, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 18 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Intermittent Claudication
Interventions: Metformin ER, placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 35 Years to 89 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Wound, Venous Leg Ulcer, Diabetic Foot Ulcer, Arterial Leg Ulcer
Interventions: geko device; Device
Lead sponsor: Firstkind Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Peripheral Arterial Disease
Interventions: Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA); Drug · Behavioral · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 40 Years to 80 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Critical Limb Ischemia, Ischemia, Leg Ulcer
Interventions: pVGI.1 (VEGF-2); Genetic
Lead sponsor: Losordo, Douglas, M.D.; Individual
Eligibility: 21 Years and older
Timeline: Ends 2008
U.S. locations: 3
States / cities: Birmingham, Alabama • Boston, Massachusetts • Minneapolis, Minnesota

Conditions: Peripheral Arterial Disease, Diabetic Foot Ulcer
Interventions: PDA-002; Biological
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 9 more

Conditions: Peripheral Arterial Disease
Interventions: Walking with poles, Walking exercise; Behavioral
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 21 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Hines, Illinois

Conditions: Peripheral Arterial Disease, Intermittent Claudication
Interventions: Home-based leg heat therapy; Device
Lead sponsor: Purdue University; Other
Eligibility: 60 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Peripheral Artery Disease (PAD)
Interventions: Segmental pulse arrival time assessment; Device
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Compartment Syndrome of Leg, Extracorporeal Membrane Oxygenation Complication, Limb Ischemia, Limb Ischemia, Critical
Interventions: MY01 + Standard of Care, 14-Gauge Slit Catheter + Standard of Care, Standard of Care; Device · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Critical Limb Ischemia, Lower Limb Amputation Knee, Peripheral Arterial Disease
Interventions: Active Arm N-acetyl cysteine (NAC), Placebo Arm; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 30 Years to 90 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cardiovascular Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Up to 99 Years
Enrollment: 7,829 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Intermittent Claudication, Arteriosclerosis
Interventions: DNA Plasmid Vector, EW-A-401 DNA Plasmid Vector; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 3
States / cities: Birmingham, Alabama • Bethesda, Maryland • Madison, Wisconsin

Conditions: Critical Limb Ischemia, Peripheral Vascular Disease
Interventions: Mesendo; Biological
Lead sponsor: TCA Cellular Therapy; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Covington, Louisiana

Conditions: Arterial Occlusive Diseases
Interventions: alfimeprase; Drug
Lead sponsor: ARCA Biopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Critical Limb Ischemia
Interventions: Oxygenesys(TM) Dissolved Oxygen Dressing; Device
Lead sponsor: Halyard Health; Industry
Eligibility: 21 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Intermittent Claudication, Peripheral Vascular Disease
Interventions: Gingko Biloba (Herb); Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Stanford, California

Conditions: Peripheral Arterial Disease (PAD)
Interventions: WIRION; Device
Lead sponsor: Gardia Medical; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 8
States / cities: Denver, Colorado • Davenport, Iowa • New Orleans, Louisiana + 5 more

Conditions: Peripheral Arterial Disease, Lower Extremity Arterial Disease
Interventions: EverFlex™ Self-Expanding Peripheral Stent System; Device
Lead sponsor: Medtronic Endovascular; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 23
States / cities: Phoenix, Arizona • Modesto, California • Sacramento, California + 20 more

Conditions: PAD, PAD - Peripheral Arterial Disease
Interventions: Lower-Extremity Heat Therapy, Sham Lower-Extremity Heat Therapy; Device
Lead sponsor: Aquilo Sports, LLC; Industry
Eligibility: 50 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Arterial Disease of Legs, Below-the-knee Obstruction, PAD - Peripheral Arterial Disease
Interventions: MagicTouch PTA Sirolimus drug coated balloon, Placebo balloon angioplasty; Device
Lead sponsor: Concept Medical Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 29
States / cities: Scottsdale, Arizona • Los Angeles, California • Clearwater, Florida + 22 more

Conditions: Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication &#X7C; Blood or Tissue &#X7C; Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 12,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 23
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 18 more

Search by objective public record fields.

Pilot Study of PRT-201 Following Angioplasty in Patients With Peripheral Artery Disease (PAD)

Comparison of Prosthetic Femoropopliteal Bypass Versus Viabahn Endoprosthesis for Treatment of Symptomatic Femoral Artery Occlusive Disease

LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies

MetfOrmin BenefIts Lower Extremities With Intermittent Claudication

Geko™ Cross Therapy Registry - Wound

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

VEGF Gene Transfer for Critical Limb Ischemia

Study of PDA-002 in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcers

Polestriding Versus Walking for Subjects With Poor Leg Circulation

A New Heat Therapy Device for Home-based Leg Heating in Patients With Lower-extremity Peripheral Artery Disease

Detecting Peripheral Artery Disease With the Pulse

Continuous Compartment Pressure Monitoring for Compartment Syndrome in VA-ECMO Patients

N-Acetyl-Cysteine (NAC) for Healing of Amputation Stumps in the Setting of Diabetes

Evaluation of Patients With Heart Disease Not Eligible for Research Protocols

EW-A-401 to Treat Intermittent Claudication

Combination Stem Cell Therapy for the Treatment of Severe Leg Ischemia

Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery

Dissolved Oxygen Dressing to Improve Chronic Wound Healing After Revascularization for Critical Limb Ischemia

Extract of Ginkgo Biloba (EGB 761) and Vascular Function

Evaluation of WIRION™ EPS in Lower Extremities Arteries

EverFlex Post Approval Study

Home-Based Lower-Extremity Heat Therapy for Walking Function in Peripheral Artery Disease

Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease

The Myelin Disorders Biorepository Project